Welcome!
OUE Lippo Healthcare
Future of the economy
Proxies to an ageing Asia
The two main Singapore proxies to an ageing Asia are ParkwayLife REIT and First REIT
March 23, 2023
Results
OUE doubles 2HFY2022 earnings to $ 101.2 million
OUE closed March 1 at $1.23, versus its NAV as at Dec 31 2022 of $4.35.
March 01, 2023
Results
OUE Lippo Healthcare reports FY2022 earnings of $32.5 million
The company's two hospital JVs in China are on track to open later this year and in 2024
February 27, 2023
Healthcare
OUE and OUE Lippo Healthcare ink partnership with 3 Singapore medical specialist groups
The partnership will see OUE and OUELH spend about $31 million to buy its 60% stake.
May 23, 2022
REITs
First REIT unveils new growth strategy; announces acquisition of 12 Japan nursing homes for JPY24.2 bil
The acquisition marks First REIT's maiden foray into the Japan nursing home market.
December 08, 2021
Results
One-off loan conversion pushes OUE Lippo Healthcare's 1H2021 earnings to $113.8 million
Excluding the gain, earnings came in at $3.67 million, reversing from the $1.26 million in losses seen in the previous year.
August 02, 2021
Funds
OUE Lippo Healthcare launches recapitalisation plan in bid to build sustainable capital structure
Shares in OUE Lippo Healthcare closed flat at 3.7 cents on Feb 23.
February 23, 2021
REITs
For First REIT investors, it is either restructure or default
First REIT's unitholders have little choice but to vote a for a restructure despite a dilutive rights issue.
January 15, 2021
Results
OUE Lippo Healthcare swings back into the black in 1Q
SINGAPORE (May 8): OUE Lippo Healthcare (OUE LH) has posted $0.2 million earnings, reversing from its 1Q18 loss of $2.7 million due to lower finance costs, higher other income as well as higher share of results of equity-accounted investees.
May 08, 2019
Broker's Calls
OUE Lippo Healthcare started at 'buy' on improving earnings visibility
SINGAPORE (Mar 11): Soochow CSSSD Capital Markets (SCCM) is starting coverage on OUE Lippo Healthcare (OUE LH) at “buy” with a target price of 8.8 cents, while forecasting a 25.2% earnings per share (EPS) CAGR from FY19-22E as the group enters a “du
March 11, 2019